Clinical Trial Update: Study of High-Dose Rituximab With Temozolomide as Treatment for Primary Central Nervous System (CNS) Lymphoma [Phase 2]

View source ↗

Summary

A Phase 2 study evaluating high-dose rituximab with temozolomide for Primary Central Nervous System Lymphoma was terminated; results were posted in February 201…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Central Nervous System Lymphoma

Drugs mentioned

• Rituxan (rituximab)
• Temodar (Temozolomide)

Snippet

Sponsor: SCRI Development Innovations, LLC | Conditions: Primary Central Nervous System Lymphoma | Phase 2 | Status: TERMINATED | Results posted: 2017-02-07